Skip to main content

Table 3 Comparison of laboratory findings between SSc patients with and without GI manifestations

From: Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies

 SSc with GI manifestations (n = 19)SSc without GI manifestations (n = 31)p value
Seropositive for Anti-gAChRα3 Abs (%)4 (21.1)3 (9.7)0.273
Seropositive for Anti-gAChRβ4 Abs (%)1 (5.3)0 (0.0)0.216
Anti-gAChRα3 Abs (A.I.)0.771 ± 0.8890.452 ± 0.4810.001*
Anti-gAChRβ4 Abs (A.I.)0.424 ± 0.3630.316 ± 0.1600.318
Other Abs 
ACA (+) (%)8 (42.1)16 (51.6)0.799
Anti-Scl70 Abs (+) (%)6 (31.6)6 (19.4)0.521
Other Abs (+) (%)2 (10.5)4 (12.9)1.000
Negative (%)3 (15.8)6 (16.1)1.000
Other laboratory data
 IgG (mg/dL)1641.9 ± 440.91536.4 ± 371.50.399
 KL-6 (U/mL)624.0 ± 692.3560.2 ± 649.50.699
 NT-proBNP (pg/mL)211.5 ± 372.7202.7 ± 273.00.757
 %FVC101.2 ± 20.699.4 ± 24.50.805
 FEV1.0%83.1 ± 9.178.0 ± 17.20.120
 %DLCO70.5 ± 21.970.6 ± 17.20.992
 DLCO/VA81.0 ± 19.885.5 ± 16.30.427
 TR-PG26.7 ± 9.923.3 ± 9.30.259
 Estimated PA systolic pressure30.1 ± 6.428.4 ± 9.30.539
 EF71.6 ± 6.570.6 ± 6.00.611
Serum biomarkers
 VEGF (pg/mL)642.4 ± 510.5389.6 ± 423.00.038*
 PIGF (pg/mL)15.7 ± 4.814.7 ± 6.30.270
 GDF-15 (pg/mL)1482.4 ± 906.91422.2 ± 947.00.366
 PTX3 (ng/mL)3.3 ± 1.72.8 ± 1.00.414
 Endostatin (ng/mL)85.3 ± 20.285.4 ± 20.00.990
 TGFβ110,580.8 ± 7998.214,707.5 ± 8058.70.060
  1. *p < 0.05 was considered statistically significant
  2. Abbreviations: Abs autoantibodies, ACA anti-centromere antibodies, DLCO diffusing capacity of lung for carbon monoxide, EF ejection fraction, FEV forced expiratory volume, FVC forced vital capacity, gAChR ganglionic acetylcholine receptor, GDF-15 growth differentiation factor-15, GI gastrointestinal, PA pulmonary artery, PIGF placenta growth factor, PTX3 pentraxin 3, SSc systemic sclerosis, TGFβ1 transforming growth factor β1, TR-PG tricuspid regurgitation pressure gradient, VEGF vascular endothelial growth factor